FilingReader Intelligence
InnoCare Pharma revenue jumps 74% on drug sales
August 19, 2025 at 10:41 AM UTC•By FilingReader AI
InnoCare Pharma reported 74.3% revenue growth to RMB731.4 million for the six months ended June 30, up from RMB419.7 million previously. Growth was driven by Orelabrutinib sales rising 52.8% to RMB637.3 million.
The company's adjusted loss decreased significantly to RMB15,504 from RMB242,992 year-over-year. Key approvals included Orelabrutinib for first-line CLL/SLL treatment and Tafasitamab for relapsed DLBCL.
InnoCare maintains RMB7.7 billion cash to fund future development.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:9969•Hong Kong Exchange
News Alerts
Get instant email alerts when InnoCare Pharma publishes news
Free account required • Unsubscribe anytime